Results 201 to 210 of about 62,343 (221)
Some of the next articles are maybe not open access.
The pneumococcal protein conjugate vaccines
The Journal of Pediatrics, 2000to develop the first licensed pneumococcal vaccine, consisting of 14 purified capsular polysaccharide antigens representing the most prevalent disease-associated serotypes. Coverage was improved by the addition of 9 more purified polysaccharide antigens, resulting in the currently licensed 23valent pneumococcal capsular polysaccharide vaccine.
Timothy R. Peters, Kathryn M. Edwards
openaire +3 more sources
PolysaccharicbConjugate Vaccines
2003It was recognized early this century that small molecules, called haptens, can be made immunogenic after conjugation to carrier proteins (1), This principle was thereafter applied successfully to improve the rmmunogenicity of (poly)saccharides (2, 3). We now know that the carrier proteins ensure the involvement of T-helper lymphocytes in the activation
Odo de Weers +6 more
openaire +3 more sources
Conjugate vaccines: practice and theory
Springer Seminars in Immunopathology, 1993Conjugate vaccines have already had a major impact on vaccination of infants against H. influenzae type b. The impact of conjugate vaccines will continue to grow as we apply this technology to other important diseases. The design of these vaccines will become more efficient and rational as we continue to understand the various facets and immunological ...
openaire +3 more sources
Immunogenicity of pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 2000Prevention of pneumococcal infections is a public health priority because of the high impact of the disease and because of the increasing problems due to antimicrobial resistance. Traditional vaccines, consisting of purified capsular polysaccharides (PSs) of Streptococcus pneumoniae, are not immunogenic in young children.
openaire +3 more sources
Conjugate pneumococcal vaccines: an overview
Medical Journal of Australia, 2000A seven-valent conjugate pneumococcal vaccine has been shown to have dramatic efficacy against invasive pneumococcal disease and lesser efficacy against otitis media and pneumonia. This vaccine was licensed for use in infants in the United States in February 2000 and is recommended there for routine use in infants and catch-up vaccination in high-risk ...
openaire +3 more sources
Meningococcal tetravalent conjugate vaccine
Expert Opinion on Biological Therapy, 2008Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. Since 1981, a tetravalent meningococcal polysaccharide vaccine has been available in the US but it has been limited to high-risk patients and outbreak settings. In 2005, a tetravalent polysaccharide meningococcal conjugate vaccine (MCV4) was licensed for routine use in the US.
openaire +3 more sources
Pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 1999Merja Anttila, Juhani Eskola
openaire +6 more sources
Pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 2000openaire +3 more sources